![](/wp-content/uploads/2023/11/Screenshot-2023-11-13-at-1.27.30-PM.png)
$599
AHA 2023: Roche/Alnylam, Amgen, Amarin, Esperion, and Lexicon Present New Data; Cleerly Partner Participation in TRANSFORM HF Trial
A series of CVRM-related news items have been observed at AHA 2023 from Roche/Alnylam, Amgen, Amarin, Esperion, Lexicon, and Cleerly. Below, FENIX provides highlights and insights into the respective news items.